Gilead expands cancer pipeline with Vir deal: Gilead Sciences stock gains 1.92 percent
Published on 10/15/2026 at 09:48 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSPipeline expansion and upcoming results
- Vir announced three solid-tumor candidates with Gilead on October 14, 2026.
- Second-quarter revenue reached USD 7.80 billion against USD 7.40 billion expected.
- Gilead Sciences stock trades at EUR 138.93 at 9:36 a.m. CEST at Lang & Schwarz on October 15, 2026, 1.92 percent above the Xetra close of October 14, 2026.
Gilead Sciences (ISIN US3755581036) stock was trading at EUR 138.93 at Lang & Schwarz on October 15, 2026, 1.92 percent above the Xetra close of October 14, 2026 at EUR 136.32. The move followed a new oncology collaboration with Vir Biotechnology. RTT News reported on October 14, 2026 that the companies agreed to discover three dual-masked T-cell engagers for solid tumors.
What does the deal add?
Gilead will receive an exclusive license to develop and commercialize the candidates, while Vir handles discovery, design and optimization. Vir is eligible for up to USD 135 million in upfront and near-term preclinical milestone payments, plus as much as USD 1.74 billion in later development, regulatory and commercial milestones, according to RTT News. The structure gives Gilead control of later development and commercialization but leaves the candidates at an early discovery stage.
Revenue beat came first
Gilead's second-quarter 2026 revenue reached USD 7.80 billion, above the USD 7.40 billion consensus estimate, while adjusted earnings per share came in at negative USD 6.75 versus negative USD 7.25 expected, according to MarketBeat. The revenue comparison matters because it shows commercial growth even as acquisition-related charges weighed on reported earnings. BofA Securities raised its price target from USD 162.00 to USD 164.00 on October 12, 2026 while keeping a Buy rating, Investing.com reported.
Three dated steps
On August 3, 2026, Gilead reported second-quarter revenue of USD 7.80 billion against USD 7.40 billion expected, according to MarketBeat. On October 12, 2026, BofA lifted its target to USD 164.00 from USD 162.00, according to Investing.com. On October 14, 2026, Vir announced the three-candidate collaboration with up to USD 1.74 billion in later milestones, as RTT News reported.
Next reporting date
Gilead is expected to report third-quarter 2026 results on October 29, 2026, after the market closes, with a conference call scheduled for 4:30 p.m. ET, according to MarketBeat. Analysts expect USD 7.79 billion in revenue and USD 2.17 in earnings per share for that quarter.
Stock price and pipeline risk
The Vir agreement adds oncology optionality, but the candidates still require discovery and clinical development before they can contribute revenue. Gilead Sciences stock was trading at EUR 138.93 at Lang & Schwarz on October 15, 2026 at 9:36 a.m. CEST, 1.92 percent above the Xetra close of October 14, 2026 at EUR 136.32. The further course of trading is shown by the continuously updated real-time quote of Gilead Sciences stock.
Gilead Sciences stock facts
- Company: Gilead Sciences, Inc.
- ISIN: US3755581036
- Ticker: GILD
- Primary exchange: Nasdaq
- Price Lang & Schwarz (as of October 15, 2026, 9:36 a.m. CEST): EUR 138.93
- Change versus Xetra close: plus 1.92 percent
- Xetra close (October 14, 2026): EUR 136.32
- Market capitalization: EUR 171.8 billion (as of October 15, 2026)
- Sector / Industry: Healthcare / Drug Manufacturers - General
Market context: Market report Nasdaq Composite.
